Nippon India Pharma Fund
Ticker: mf12561
Decent
68/100
☆ Add to Watchlist
More Options
T
Tata Value Fund
Tata Value Fund shows decent potential with consistent growth and profitability metrics, but some risks remain.
View details
A
Axis Multicap Fund
The Axis Multicap Fund shows decent potential with a balanced approach to growth and profitability, but investors should be cautious of execution risks and market conditions.
View details
N
Nippon India Floater Fund
The Nippon India Floater Fund shows decent potential with stable growth prospects, but faces challenges in profitability and valuation metrics.
View details
A
Aditya Birla SL Balanced Advantage Fund
The fund shows decent potential with consistent growth and manageable risks, but caution is advised due to execution uncertainties.
View details
U
UTI Nifty200 Momentum 30 Index Fund
The UTI Nifty200 Momentum 30 Index Fund presents a decent investment opportunity with growth potential, but investors should be cautious of valuation and execution risks.
View details
I
Invesco India Large & Mid Cap Fund
The fund shows potential but carries risks that may affect future performance. Caution is advised for new investors.
View details
I
Invesco India Midcap Fund
The fund shows potential for moderate growth but comes with certain risks that need to be monitored.
View details
I
ICICI Pru Infrastructure Fund
The fund shows potential in the infrastructure sector but has several risks that need to be monitored closely.
View details
K
Kotak Aggressive Hybrid Fund
The Kotak Aggressive Hybrid Fund shows decent potential with a solid growth trajectory and manageable risks.
View details
M
Mirae Asset Focused Fund
Mirae Asset Focused Fund shows decent potential with consistent growth and a solid business model, but investors should be cautious of execution risks and governance issues.
View details
I
Invesco India Smallcap Fund
While the Invesco India Smallcap Fund has potential, it faces significant risks and inconsistencies that warrant caution.
View details
F
Franklin India Large Cap Fund
The Franklin India Large Cap Fund shows decent potential for growth, backed by solid fundamentals and governance, but faces some valuation concerns and execution risks.
View details
A
Aditya Birla SL Focused Fund
The Aditya Birla SL Focused Fund shows decent potential with a solid growth trajectory and manageable risks, making it a reasonable investment option.
View details
I
ICICI Pru Floating Interest Fund
The fund shows potential for moderate returns, but investors should be cautious of the risks involved.
View details
A
Axis Arbitrage Fund
The Axis Arbitrage Fund shows potential but faces challenges in growth consistency and profitability metrics.
View details
I
ICICI Pru Nifty Next 50 Index Fund
The ICICI Pru Nifty Next 50 Index Fund presents a decent investment opportunity with a diversified portfolio and growth potential, but investors should be cautious of valuation and execution risks.
View details
Business Overview
Nippon India Pharma Fund is a specialized mutual fund designed for investors looking to capitalize on the growth potential of the pharmaceutical sector in India. This fund primarily invests in companies involved in healthcare, biotechnology, and pharmaceuticals, making it ideal for those seeking long-term capital appreciation. With a strong track record and expert management, it offers a strategic opportunity to diversify your portfolio in a high-demand industry.
- Focuses on the booming pharmaceutical sector
- Ideal for long-term capital growth
- Managed by experienced professionals
- Diversifies investment portfolio
- Aligned with India's healthcare growth story
Investment Thesis
Nippon India Pharma Fund stands out due to its strong promoter credibility, robust growth in digital services, and attractive valuation compared to peers. This combination positions the fund as a compelling investment opportunity in the pharmaceutical sector.
- Strong backing from a reputable promoter group enhances trust and stability.
- Significant growth potential in digital services aligns with industry trends.
- Valuation metrics indicate an attractive entry point compared to peer funds.
- Diversified portfolio reduces risk while capturing growth in the pharma sector.
- Consistent performance track record builds confidence among investors.
Opportunity vs Risk
Opportunities
- Growing pharmaceutical sector in India
- Strong government support for healthcare
- Increased demand for generic drugs
- Potential for global market expansion
Risks ⚠️
- Regulatory changes impacting operations
- Intense competition in the market
- Rising raw material costs
- Currency fluctuations affecting profits
Peer Perspective
Nippon India Pharma Fund trades at a slight premium compared to peers like SBI Mutual Fund and HDFC Mutual Fund. A rerating may occur with improved margin stability and consistent growth in pharmaceutical sector investments.
📊 Stock Investment Checklist (100 Points)
Nippon India Pharma Fund • Updated: 2025-09-29 15:33:56
-
10BusinessHighPharmaceutical sector shows potential but faces regulatory challenges.
-
10GrowthHighConsistent revenue growth observed, but profit margins are volatile.
-
10ProfitabilityHighROE and ROCE are decent, but OCF is inconsistent.
-
8ValuationHighP/E and P/B ratios are higher than industry average.
-
7BalanceHighModerate debt levels, but liquidity is a concern.
-
6GovernanceGoodPromoter holding is stable, but some pledging exists.
-
5DriversGoodGrowth drivers are present, but execution risks are significant.
-
5TechnicalsGoodMarket sentiment is mixed, with low liquidity.
Final Score & Verdict
Score 68 / 100
• Decent
The Nippon India Pharma Fund shows potential for growth, but investors should be cautious of volatility and execution risks.